Keywords: BioDelivery Sciences, Suboxone, Buprenorphine, Naloxone, Reckitt Benckiser, Generic competition, Opioid dependence
BioDelivery Sciences set to file for Suboxone copy drug 2nd-qtr 2013
Article | 17 September 2012
US drugmaker BioDelivery Sciences International (Nasdaq: BDSI) announced a positive outcome of its pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
